PhotoCure
Photocure ASA is a Norwegian specialty pharmaceutical company focused on photodynamic technology for bladder cancer diagnosis and management. The company develops and commercializes Hexvix and Cysview, optical imaging agents used with blue light cystoscopy to detect non-muscle invasive bladder cancer. Main revenue drivers include commercial sales of Hexvix and Cysview kits to hospitals and clinics alongside partner royalty fees. Photocure serves urologists, hospital surgical departments, diagnostic centers, and bladder cancer patients across North America, Europe, and international markets. The company holds a market-leading position as a global pioneer in photodynamic diagnosis of bladder cancer. Headquartered in Oslo, Norway, Photocure ASA is listed on Oslo Bors.
7 of the funds FundTelligence covers report a position in PhotoCure.
- Legal name
- PhotoCure ASA
- Sector
- Health Care
- Country
- Norway
- Funds holding it
- 7
Funds holding PhotoCure
- Lannebo Sverige Plus — Lannebo · 0.96 % (full portfolio disclosed, June 2026)
- Handelsbanken Norden Index Criteria — Handelsbanken · 0.07 % (full portfolio disclosed, October 2026)
- KLP AksjeNorge Aktiv — KLP · 0.07 % (full portfolio disclosed, June 2026)
- KLP AksjeNorge Indeks — KLP · 0.06 % (full portfolio disclosed, June 2026)
- DNB Norge Indeks — DNB · 0.05 % (full portfolio disclosed, September 2026)
- Danske Invest Norway Index Restricted — Danske Invest · 0.05 % (full portfolio disclosed, September 2026)
- Storebrand Indeks Norge — Storebrand · 0.04 % (full portfolio disclosed, October 2026)